|
|
Post by mnkdfann on May 29, 2019 11:00:47 GMT -5
seekingalpha.com/article/4266973-eli-lilly-cutting-price-humalogThis is the interesting bit: "[W]hy even waste the time manufacturing a generic when you already manufacture the brand? Well, with Humalog, Lilly can squeeze out competition by offering higher rebates to PBMs to exclude competitors from insurance coverage." "[D]rug companies can force out competition entirely by a combination of price competition and higher rebates, artificially constricts supply, and [push] prices higher than otherwise" Some reasons Afrezza has trouble competing in the marketplace.
|
|
|
|
Post by travis1953 on May 29, 2019 21:13:00 GMT -5
What shocked me was the sentence, "No wonder Admelog has only sold $93M since launch in the second quarter of 2018, according to the latest data from Sanofi." The author appears disappointed in that number but, I mean, it hasn't been on the market long enough to even make it onto most formularies. It's taken afrezza four and a half years just to approach 93 million in total sales. I clearly don't understand the mechanics of the diabetes market place.
|
|
|
|
Post by traderdennis on May 29, 2019 22:24:53 GMT -5
What shocked me was the sentence, "No wonder Admelog has only sold $93M since launch in the second quarter of 2018, according to the latest data from Sanofi." The author appears disappointed in that number but, I mean, it hasn't been on the market long enough to even make it onto most formularies. It's taken afrezza four and a half years just to approach 93 million in total sales. I clearly don't understand the mechanics of the diabetes market place. Afrezza is approaching 50 million not 93. There is a milestone bonus payable to Deerfield probably 1st quarter 2020 for 50 million in cumulative sales. |
|
|
|
Post by mnkdfann on May 29, 2019 22:33:52 GMT -5
What shocked me was the sentence, "No wonder Admelog has only sold $93M since launch in the second quarter of 2018, according to the latest data from Sanofi." The author appears disappointed in that number but, I mean, it hasn't been on the market long enough to even make it onto most formularies. It's taken afrezza four and a half years just to approach 93 million in total sales. I clearly don't understand the mechanics of the diabetes market place. Afrezza is approaching 50 million not 93. There is a milestone bonus payable to Deerfield probably 1st quarter 2020 for 50 million in cumulative sales. liane's chart shows $90+ million in cumulative sales. mnkd.proboards.com/attachment/download/1986I'm sure there is an explanation for the discrepancy, though I don't know what it would be. Gross versus net? |
|
|
|
Post by traderdennis on May 30, 2019 8:05:44 GMT -5
Afrezza is approaching 50 million not 93. There is a milestone bonus payable to Deerfield probably 1st quarter 2020 for 50 million in cumulative sales. liane's chart shows $90+ million in cumulative sales. mnkd.proboards.com/attachment/download/1986I'm sure there is an explanation for the discrepancy, though I don't know what it would be. Gross versus net? Lianes chart is retail sales from symphony. The figure I put was gross revenue. |
|
|
|
Post by agedhippie on May 30, 2019 9:01:16 GMT -5
Lianes chart is retail sales from symphony. The figure I put was gross revenue. The more interesting number is $63M, that is last quarters sales. Admelog was launched in April 2018 so the cumulative sales ($103M if you convert to USD) were for a partial launch year. This illustrates the cost to Afrezza of not educating the market. |
|
|
|
Post by ktim on Jun 2, 2019 18:49:55 GMT -5
What shocked me was the sentence, "No wonder Admelog has only sold $93M since launch in the second quarter of 2018, according to the latest data from Sanofi." The author appears disappointed in that number but, I mean, it hasn't been on the market long enough to even make it onto most formularies. It's taken afrezza four and a half years just to approach 93 million in total sales. I clearly don't understand the mechanics of the diabetes market place. Afrezza is approaching 50 million not 93. There is a milestone bonus payable to Deerfield probably 1st quarter 2020 for 50 million in cumulative sales. Who would have imagined they'd still be on life support when a milestone becomes due for revenue? I used to imagine we'd be cheering upon hitting each milestone rather than wondering where the money to pay is coming come. |
|
